Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$972.12K-$972.12KN/M vs Q3 2023 EPS Diluted-$11.38-$11.38N/M vs Q3 2023 Operating Income-$1,006,471N/M Operating Cash Flowderived-$1,356,672N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end